2012
DOI: 10.1007/s00210-012-0766-7
|View full text |Cite
|
Sign up to set email alerts
|

Problems associated with the use of commercial and non-commercial antibodies against the histamine H4 receptor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2012
2012
2016
2016

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 29 publications
0
9
0
Order By: Relevance
“…Specifically, it has been shown that many antibodies against β 3 -adrenoceptors (Pradidarcheep et al 2009;Cernecka et al 2012), other β-adrenoceptor subtypes (Hamdani and van der Velden 2009) or other G-protein-coupled receptors in general (Pradidarcheep et al 2008;Michel et al 2009;Adams et al 2012;Beermann et al 2012;Neumann et al 2012;Yu and Hill 2013;Cecyre et al 2014;Talmont and Mouledous 2014;Böhmer et al 2014), in many, if not most cases, lack selectivity for their cognate receptors when tested based on stringent criteria. A well-validated monoclonal antibody against β 3 -adrenoceptors (Chamberlain et al 1999) unfortunately never became available commercially and no longer is available from the original investigators.…”
mentioning
confidence: 99%
“…Specifically, it has been shown that many antibodies against β 3 -adrenoceptors (Pradidarcheep et al 2009;Cernecka et al 2012), other β-adrenoceptor subtypes (Hamdani and van der Velden 2009) or other G-protein-coupled receptors in general (Pradidarcheep et al 2008;Michel et al 2009;Adams et al 2012;Beermann et al 2012;Neumann et al 2012;Yu and Hill 2013;Cecyre et al 2014;Talmont and Mouledous 2014;Böhmer et al 2014), in many, if not most cases, lack selectivity for their cognate receptors when tested based on stringent criteria. A well-validated monoclonal antibody against β 3 -adrenoceptors (Chamberlain et al 1999) unfortunately never became available commercially and no longer is available from the original investigators.…”
mentioning
confidence: 99%
“…In response to this, Gutzmer et al disagreed with some of the conclusions since they felt that work from their laboratory using one of the antibodies, had proved its efficacy and that technical differences in the experimental designs were responsible for discrepant results (Gutzmer et al, 2012). While conceding some points, the Beermann group nonetheless strongly defended the primary conclusions (Neumann et al, 2012). This debate emphasizes the difficulty of ‘proving’ that antibodies don’t work but is worth having in an attempt to ‘raise the bar’ overall for what is generally considered satisfactory evidence of specificity.…”
Section: Discussionmentioning
confidence: 99%
“…The specificity of antibodies is a general problem, especially in case of transmembrane proteins like GPCRs . Several commercially available H 4 R antibodies lack specificity , which was extensively discussed in a scientific dispute (Gutzmer et al, 2012;Neumann et al, 2012). Lack of antibody specificity was not only reported for H 4 R, but also for several other GPCR types including dopamine receptors (Bodei et al, 2009), P2Y6 purinoceptors (Yu and Hill, 2013) or muscarinic and adrenergic receptors (Pradidarcheep et al, 2009) and the discussion is still ongoing (B€ ohmer et al, 2014;Talmont and Moul edous, 2014).…”
Section: Methodsmentioning
confidence: 99%